HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Teru Hideshima Selected Research

Multiple Myeloma

6/2022Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
1/2022Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
10/2021Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.
1/2021Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
1/2021Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
1/2021ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.
1/2021Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
11/2020The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
1/2020Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
1/2019A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Teru Hideshima Research Topics

Disease

219Multiple Myeloma
06/2022 - 01/2002
109Neoplasms (Cancer)
01/2021 - 01/2002
13Hematologic Neoplasms (Hematological Malignancy)
06/2014 - 06/2003
7Plasmacytoma
03/2012 - 09/2002
6Chromosomal Instability (Chromosome Stability)
09/2015 - 07/2002
6Lymphoma (Lymphomas)
06/2014 - 10/2003
5Necrosis
01/2017 - 01/2002
4Breast Neoplasms (Breast Cancer)
08/2021 - 01/2014
4Waldenstrom Macroglobulinemia (Macroglobulinemia)
12/2016 - 06/2007
4Bone Diseases (Bone Disease)
04/2013 - 01/2007
4Inflammation (Inflammations)
01/2008 - 06/2003
3Carcinogenesis
01/2018 - 10/2009
3Leukemia
06/2014 - 01/2004
3Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
12/2012 - 02/2005
3Fatigue
01/2012 - 08/2010
3Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
07/2009 - 09/2005
2Disease Progression
11/2010 - 09/2009
2Bone Resorption
04/2008 - 10/2007

Drug/Important Bio-Agent (IBA)

67Bortezomib (Velcade)FDA Link
01/2021 - 05/2002
36Proteasome InhibitorsIBA
01/2021 - 05/2002
25Biological ProductsIBA
10/2021 - 05/2002
25Lenalidomide (CC 5013)FDA Link
01/2021 - 11/2002
24Dexamethasone (Maxidex)FDA LinkGeneric
03/2014 - 02/2002
20Interleukin-6 (Interleukin 6)IBA
01/2020 - 05/2002
20Proteasome Endopeptidase Complex (Proteasome)IBA
12/2018 - 10/2002
18Thalidomide (Thalomid)FDA Link
01/2012 - 01/2002
18CytokinesIBA
11/2010 - 05/2002
15Proteins (Proteins, Gene)FDA Link
01/2016 - 05/2003
15NF-kappa B (NF-kB)IBA
07/2013 - 05/2002
14Pharmaceutical PreparationsIBA
03/2016 - 11/2002
12Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
02/2008 - 05/2002
10Immunomodulating AgentsIBA
01/2021 - 05/2002
9Melphalan (Alkeran)FDA LinkGeneric
03/2016 - 07/2002
8Histone Deacetylase InhibitorsIBA
01/2018 - 05/2003
8Phosphotransferases (Kinase)IBA
11/2014 - 11/2003
8perifosineIBA
08/2012 - 05/2006
7Monoclonal AntibodiesIBA
11/2020 - 05/2003
7Histone Deacetylases (Histone Deacetylase)IBA
01/2020 - 10/2003
7DNA (Deoxyribonucleic Acid)IBA
09/2017 - 03/2003
7Insulin-Like Growth Factor I (IGF-1)IBA
02/2008 - 08/2002
7Doxorubicin (Adriamycin)FDA LinkGeneric
06/2007 - 07/2002
6Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2014 - 01/2003
5EnzymesIBA
01/2018 - 10/2003
5AntigensIBA
01/2018 - 05/2004
5Heat-Shock Proteins (Heat-Shock Protein)IBA
01/2015 - 10/2002
5InterleukinsIBA
01/2009 - 05/2004
5Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
07/2007 - 04/2003
5CaspasesIBA
02/2007 - 11/2003
5Telomerase (Telomerase Reverse Transcriptase)IBA
04/2004 - 07/2002
4pomalidomideIBA
01/2021 - 09/2006
4Transcription Factors (Transcription Factor)IBA
01/2019 - 06/2002
4Sirolimus (Rapamycin)FDA Link
11/2014 - 12/2004
4VorinostatFDA Link
01/2013 - 05/2003
4Immunoglobulins (Immunoglobulin)IBA
12/2009 - 08/2004
4Protein Kinase CIBA
02/2009 - 05/2004
4Antineoplastic Agents (Antineoplastics)IBA
05/2008 - 09/2002
4p38 Mitogen-Activated Protein KinasesIBA
05/2008 - 01/2003
4Insulin-Like PeptidesIBA
02/2006 - 07/2002
3Histones (Histone)IBA
10/2021 - 05/2011
3UbiquitinIBA
01/2019 - 01/2008
3Protein Kinases (Protein Kinase)IBA
01/2017 - 05/2006
3TOR Serine-Threonine KinasesIBA
08/2014 - 11/2006
3Peptides (Polypeptides)IBA
01/2014 - 06/2003
3Immunoglobulin G (IgG)IBA
08/2012 - 07/2005
3Aurora Kinase AIBA
05/2011 - 09/2009
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2009 - 12/2004
3Cytotoxins (Cytolysins)IBA
04/2009 - 03/2007
3enzastaurinIBA
02/2009 - 02/2007
3tanespimycin (17AAG)IBA
01/2009 - 02/2006
3GlucocorticoidsIBA
12/2007 - 01/2005
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2006 - 09/2002
3Therapeutic UsesIBA
09/2006 - 03/2004
3OligonucleotidesIBA
10/2003 - 02/2002
32-MethoxyestradiolIBA
09/2003 - 09/2002
2WT161IBA
08/2021 - 10/2017
2Growth Factor ReceptorsIBA
08/2021 - 10/2017
2CD40 Ligand (CD40L)IBA
01/2018 - 07/2005
2CateninsIBA
01/2017 - 03/2014
2Nicotinamide PhosphoribosyltransferaseIBA
12/2016 - 08/2013
2NAD (NADH)IBA
03/2016 - 10/2012
2MicroRNAs (MicroRNA)IBA
03/2016 - 03/2014
2Messenger RNA (mRNA)IBA
10/2015 - 08/2008
2Mechanistic Target of Rapamycin Complex 1IBA
11/2014 - 10/2012
2Neutralizing AntibodiesIBA
04/2013 - 03/2004
2PanobinostatIBA
01/2013 - 11/2011
2Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
10/2012 - 05/2004
2LuciferasesIBA
03/2012 - 07/2006
2Phosphatidylinositols (Phosphatidylinositol)IBA
04/2010 - 05/2006
2Caspase 3 (Caspase-3)IBA
12/2009 - 09/2005
2STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA
12/2009 - 12/2008
2beta CateninIBA
09/2009 - 02/2009
2Immunoconjugates (Immunoconjugate)IBA
06/2009 - 12/2004
2I-kappa B KinaseIBA
05/2009 - 10/2006
2Protein Isoforms (Isoforms)IBA
02/2009 - 12/2003
2Alkylating AgentsIBA
07/2008 - 08/2006
2Extracellular Matrix ProteinsIBA
02/2008 - 09/2005

Therapy/Procedure

74Therapeutics
06/2022 - 08/2002
9Drug Therapy (Chemotherapy)
12/2007 - 09/2002
3Stem Cell Transplantation
03/2007 - 07/2004
3Immunotherapy
07/2005 - 08/2003